The Lynx Group
Association for Value-Based Care

AVBCC 2020 Summit

Greg Simon, who led the Cancer Moonshot program under the Obama-Biden administration, asserts that the COVID-19 pandemic has exposed vast chasms of inequity in cancer care, and challenges listeners to think in new ways about how we deliver and pay for care.
Read More

From new approaches for sequencing therapy to preparing for an incoming tsunami of delayed diagnoses after months of missed cancer screenings, community cancer providers have a lot to manage in the era of COVID-19.
Read More

From the CMS’s Oncology Care Model to future prospects for Oncology Care First and other value-based and alternative payment models, payers share their insights on what is most likely to succeed to improve care and manage costs in oncology.
Read More

From quality-adjusted life-years to social determinants of health to the international pricing index, top experts in cancer care economics discussed strategies for achieving the Holy Grail of true value-based pricing for pharmaceuticals.
Read More

Uncertainty reigns in Washington with the upcoming election only weeks away. What can cancer care stakeholders expect from legislators and policymakers over the next several weeks, during the lame duck session, and in 2021?
Read More

The top priority for employers regarding their employees’ cancer care coverage is ensuring access to state-of-the-art care. Learn how employers are trying to close the gap between “typical” and “optimal” care.
Read More

Telling the story of the Oncology Care Model and its performance over the past 5 years through some of the best-performing practices.
Read More

On October 8, 2020, the Berkeley Research Group published a report showing that contract pharmacy participation in the 340B Drug Pricing Program grew by 4228% between 2010, when the Health Resources and Services Administration expanded the contract pharmacy program, and 2020. A week later, on October 16, 2020, a variety of stakeholders in the 340B program—covered entities, contract pharmacies, pharmaceutical manufacturers, and outside tech consultants—participated in an intense discussion of contract pharmacy growth, newly imposed manufacturer audit requirements, and ways to return 340B to its original purpose of spreading scarce federal resources and serving vulnerable patients.
Read More

Page 3 of 3

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: